Adult men and women over the age of 18 with hepatocellular carcinoma (HCC, or liver cancer) for research study.
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)
Weiss Geoffrey, R
UVa Health System, Cancer Center, Division of Hematology/Oncology seeks adult men and women over the age of 18 with hepatocellular carcinoma (HCC, or liver cancer) for research study. The purpose of the study is to see how the experimental drug combination of Erlotinib and Bevacizumab (E+B), compares to the current approved drug, Sorafenib (S). The study involves screening visit(s) to determine eligibility, blood draws, imaging scans, treatment cycles with either 1) E+B or 2) S alone, and 2 end of treatment visits. Participants may remain on the study for as long as the cancer and participant remain well, therefore, the number of visits will vary. Each participant will have at least 4 study visits (1 screening, 1 treatment visit, and 2 end of treatment visits) which will take about 2 hours of time. * Study-related experimental drugs, E+B, will be provided free of charge. * Participant and/or their insurance company will be billed for administration of Bevacizumab. Participant and/or insurance company must pay for the Sorafenib medication. Participant and/or insurance company will pay for all tests and procedures. No compensation is provided for this study. Principal Investigator: Geoffrey R. Weiss, MD